Paclitaxel and cisplatin combined with intensity-modulated radiotherapy for upper esophageal carcinoma

Radiation Oncology

Youling Gong¹  Yuquan Wei¹  Feng Peng¹  Jiang Zhu¹  Yongmei Liu¹  Lin Zhou¹  Yongsheng Wang¹  Yong Xu¹  Lan Sun¹  Lingli Tu¹ 

[1] Department of Thoracic Oncology and State Key Laboratory of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, 610041, People’s Republic of China

关键词: Intensity-modulated radiotherapy;    Cisplatin;    Paclitaxel;    Upper esophageal carcinoma;   

Others  :  1154314
DOI  :  10.1186/1748-717X-8-75

 received in 2012-09-03, accepted in 2013-03-22,  发布年份 2013

【 摘 要 】

Purpose

This study was conducted to evaluate the effectiveness and safety of intensity-modulated radiotherapy (IMRT) and concurrent paclitaxel plus cisplatin (TP regimen) for upper esophageal carcinoma.

Methods

36 patients of upper esophageal carcinoma were retrospectively analyzed. Patients were treated with IMRT (median 60 Gy) combined with concurrent TP regimen chemotherapy. The Kaplan-Meier analysis was performed in statistical analysis. Toxicities were recorded according to the NCI CTC version 3.0.

Results

36 patients aged 43–73 years (median 57 years). The median follow-up period was 14.0 months. The 1-year and 2-year survival rates were 83.3% and 42.8% respectively. The median progression-free survival (PFS) time and overall survival (OS) time were 12.0 (95% CI: 7.8–16.2 months) and 18.0 months (95% CI: 9.9–26.1 months), respectively. Grade 3 neutropenia, radiation-induced esophagitis and radiodermatitis were observed in 5 (13.9%), 3 (8.3%) and 8 (22.2%) patients respectively. There were two treatment-related deaths due to esophageal perforation and hemorrhea.

Conclusions

For those patients with upper esophageal carcinoma, IMRT combined with concurrent TP regimen chemotherapy was an effective treatment. However, more attention should be paid to the occurrence of perforation and hemorrhea.

【 授权许可】

   
2013 Tu et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Pisani P, Parkin DM, Bray F, Ferlay J: Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999, 83:18-29.
• [2]Parkin DM, Bray FI, Devesa SS: Cancer burden in the year. The global picture. Eur J Cancer 2000, 2001(37 Suppl 8):S4-S66.
• [3]Denham JW, Burmeister BH, Lamb DS, Spry NA, Joseph DJ, Hamilton CS, Yeoh E, O’Brien P, Walker QJ: Factors influencing outcome following radio-chemotherapy for oesophageal cancer. The Trans Tasman Radiation Oncology Group (TROG). Radiother Oncol 1996, 40:31-43.
• [4]Daiko H, Hayashi R, Saikawa M, Sakuraba M, Yamazaki M, Miyazaki M, Ugumori T, Asai M, Oyama W, Ebihara S: Surgical management of carcinoma of the cervical esophagus. J Surg Oncol 2007, 96:166-172.
• [5]Triboulet JP, Mariette C, Chevalier D, Amrouni H: Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg 2001, 136:1164-1170.
• [6]Wang HW, Chu PY, Kuo KT, Yang CH, Chang SY, Hsu WH, Wang LS: A reappraisal of surgical management for squamous cell carcinoma in the pharyngoesophageal junction. J Surg Oncol 2006, 93:468-476.
• [7]Chiu PW, Chan AC, Leung SF, Leong HT, Kwong KH, Li MK, Au-Yeung AC, Chung SC, Ng EK: Multicenter prospective randomized trial comparing standard esophagectomy with chemoradiotherapy for treatment of squamous esophageal cancer: early results from the Chinese University Research Group for Esophageal Cancer (CURE). J Gastrointest Surg 2005, 9:794-802.
• [8]Ajani JA, Ilson DH, Daugherty K, Pazdur R, Lynch PM, Kelsen DP: Activity of taxol in patients with squamous cell carcinoma and adenocarcinoma of the esophagus. J Natl Cancer Inst 1994, 86:1086-1091.
• [9]Ilson DH, Ajani J, Bhalla K, Forastiere A, Huang Y, Patel P, Martin L, Donegan J, Pazdur R, Reed C, Kelsen DP: Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol 1998, 16:1826-1834.
• [10]Adelstein DJ, Rice TW, Rybicki LA, Larto MA, Ciezki J, Saxton J, DeCamp M, Vargo JJ, Dumot JA, Zuccaro G: Does paclitaxel improve the chemoradiotherapy of locoregionally advanced esophageal cancer? A nonrandomized comparison with fluorouracil-based therapy. J Clin Oncol 2000, 18:2032-2039.
• [11]Polee MB, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Verweij J, Stoter G, van der Gaast A: Phase II study of bi-weekly administration of paclitaxel and cisplatin in patients with advanced oesophageal cancer. Br J Cancer 2002, 86:669-673.
• [12]Tishler RB, Schiff PB, Geard CR, Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 1992, 22:613-617.
• [13]Choy H, Rodriguez FF, Koester S, Hilsenbeck S, Von Hoff DD: Investigation of taxol as a potential radiation sensitizer. Cancer 1993, 71:3774-3778.
• [14]Leonard CE, Chan DC, Chou TC, Kumar R, Bunn PA: Paclitaxel enhances in vitro radiosensitivity of squamous carcinoma cell lines of the head and neck. Cancer Res 1996, 56:5198-5204.
• [15]van Meerten E, Muller K, Tilanus HW, Siersema PD, Eijkenboom WM, van Dekken H, Tran TC, van der Gaast A: Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer 2006, 94:1389-1394.
• [16]Orditura M, Galizia G, Napolitano V, Martinelli E, Pacelli R, Lieto E, Aurilio G, Vecchione L, Morgillo F, Catalano G, et al.: Weekly chemotherapy with cisplatin and paclitaxel and concurrent radiation therapy as preoperative treatment in locally advanced esophageal cancer: a phase II study. Cancer Invest 2010, 28:820-827.
• [17]Wang S, Liao Z, Chen Y, Chang JY, Jeter M, Guerrero T, Ajani J, Phan A, Swisher S, Allen P, et al.: Esophageal cancer located at the neck and upper thorax treated with concurrent chemoradiation: a single-institution experience. J Thorac Oncol 2006, 1:252-259.
• [18]Tong DK, Law S, Kwong DL, Wei WI, Ng RW, Wong KH: Current management of cervical esophageal cancer. World J Surg 2011, 35:600-607.
• [19]Huang SH, Lockwood G, Brierley J, Cummings B, Kim J, Wong R, Bayley A, Ringash J: Effect of concurrent high-dose cisplatin chemotherapy and conformal radiotherapy on cervical esophageal cancer survival. Int J Radiat Oncol Biol Phys 2008, 71:735-740.
• [20]Greene FL, Page DL, Fleming ID: AJCC Cancer Staging Manual. 6th edition. New York: Springer; 2002.
• [21]Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
• [22]Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler JJ, Spencer S, et al.: Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. J Am Med Assoc 1999, 281:1623-1627.
• [23]Wong RK, Malthaner R: WITHDRAWN. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev 2010, CD002092.
• [24]Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP: INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002, 20:1167-1174.
• [25]Ajani JA, Winter K, Komaki R, Kelsen DP, Minsky BD, Liao Z, Bradley J, Fromm M, Hornback D, Willett CG: Phase II randomized trial of two nonoperative regimens of induction chemotherapy followed by chemoradiation in patients with localized carcinoma of the esophagus: RTOG 0113. J Clin Oncol 2008, 26:4551-4556.
• [26]Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 2004, 22:45-52.
• [27]Safran H, Gaissert H, Akerman P, Hesketh PJ, Chen MH, Moore T, Koness J, Graziano S, Wanebo HJ: Paclitaxel, cisplatin, and concurrent radiation for esophageal cancer. Cancer Invest 2001, 19:1-7.